Carmen Joshua M, Shrivastava Shikha, Lu Zhongyan, Anderson Alexander, Morrison Elaine B, Sankhala Rajeshwer S, Chen Wei-Hung, Chang William C, Bolton Jessica S, Matyas Gary R, Michael Nelson L, Joyce M Gordon, Modjarrad Kayvon, Currier Jeffrey R, Bergmann-Leitner Elke, Malloy Allison M W, Rao Mangala
Laboratory of Adjuvant and Antigen Research, US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
US Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
NPJ Vaccines. 2021 Dec 13;6(1):151. doi: 10.1038/s41541-021-00414-4.
The emergence of variants of concern, some with reduced susceptibility to COVID-19 vaccines underscores consideration for the understanding of vaccine design that optimizes induction of effective cellular and humoral immune responses. We assessed a SARS-CoV-2 spike-ferritin nanoparticle (SpFN) immunogen paired with two distinct adjuvants, Alhydrogel or Army Liposome Formulation containing QS-21 (ALFQ) for unique vaccine evoked immune signatures. Recruitment of highly activated multifaceted antigen-presenting cells to the lymph nodes of SpFN+ALFQ vaccinated mice was associated with an increased frequency of polyfunctional spike-specific memory CD4 T cells and K spike-(539-546)-specific long-lived memory CD8 T cells with effective cytolytic function and distribution to the lungs. The presence of this epitope in SARS-CoV, suggests that generation of cross-reactive T cells may be induced against other coronavirus strains. Our study reveals that a nanoparticle vaccine, combined with a potent adjuvant that effectively engages innate immune cells, enhances SARS-CoV-2-specific durable adaptive immune T cell responses.
一些对新冠疫苗敏感性降低的变异毒株的出现,凸显了理解疫苗设计的重要性,这种设计可优化有效细胞免疫和体液免疫反应的诱导。我们评估了一种与两种不同佐剂(氢氧化铝或含QS-21的军队脂质体配方(ALFQ))配对的新冠病毒刺突-铁蛋白纳米颗粒(SpFN)免疫原,以获得独特的疫苗引发的免疫特征。在接种SpFN+ALFQ的小鼠淋巴结中,高度活化的多面抗原呈递细胞的募集与多功能刺突特异性记忆CD4 T细胞以及具有有效溶细胞功能并分布到肺部的K刺突-(539-546)特异性长寿记忆CD8 T细胞频率增加有关。该表位在严重急性呼吸综合征冠状病毒中的存在表明,可能会诱导产生针对其他冠状病毒株的交叉反应性T细胞。我们的研究表明,一种纳米颗粒疫苗与一种有效激活先天免疫细胞的强效佐剂相结合,可增强新冠病毒特异性持久适应性免疫T细胞反应。